Camysha Wright, MD
Otolaryngology · Plantation, FLNPI 1497959092
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Stryker accounts for 63.0% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $20,187, more than ten times the $1,779 reported in 2019. Among otolaryngology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $222.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$24K
- Alk-abello, Inc$10K
- Aerin Medical Inc.$2K
- Optinose US, Inc.$489
- GSK$399
- Sanofi$318
- plus $1K from 15 others
What the payments were for
- Consulting fees$21,21855%
- Speaking & faculty fees$7,70020%
- Travel & lodging$4,55612%
- Food & beverage$4,76812%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 52 | $24,119 |
| Alk-abello, Inc | 38 | $10,294 |
| Aerin Medical Inc. | 11 | $1,569 |
| Optinose US, Inc. | 16 | $489 |
| GSK | 15 | $399 |
| Sanofi | 7 | $318 |
| Acclarent, Inc | 4 | $221 |
| Neurent Medical Limited | 1 | $170 |
| Intersect ENT, Inc. | 5 | $143 |
| Regeneron Healthcare Solutions, Inc. | 3 | $98 |
| Smith+Nephew | 3 | $83 |
| Phadia US Inc. | 4 | $80 |
| Integra Lifesciences Corporation | 3 | $69 |
| Aroa Biosurgery Incorporated | 1 | $46 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $39 |
| Novartis | 2 | $36 |
| Resmed Corp | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATERA$17,063
- SCOPIS ENT$13,978
- CLARIFIX CRYOTHERAPY DEVICE$10,688
- AUDION ET DILATION SYSTEM$6,000
- CLARIFIX$6,000
- XPRESS LOPROFILE$5,438
- Odactra$4,406
- HEMOPORE$1,500
- NASOPORE$1,500
- Vivaer RF Stylus$1,242
- NEUROMARK Device$170
- NEUROMARK Radiofrequency Console$170
- XPRESS ENT DILATION SYSTEM$135
- XEROGEL NASAL/EPISTAXIS 2 PACK$135
- ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE$135
- SHAVER SYSTEM$135
- TruDi$124
- Xhance$120
- NUCALA$118
How this compares
$38,267 in reported general payments places this provider in the 95th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RyaltrisOlopatadine Hcl/Mometasone | 50 | $18,500 |
| XhanceFluticasone Propionate | 11 | $6,591 |
| Ipratropium Bromide | 148 | $6,529 |
| Azelastine Hcl | 122 | $3,843 |
| Mometasone Furoate | 41 | $3,113 |
| Fluticasone Propionate | 203 | $2,922 |
| Epinephrine | 12 | $2,690 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 171 | $1,639 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 23 | $1,447 |
| Olopatadine Hcl | 18 | $1,432 |
| Fluocinolone Acetonide Oil | 34 | $1,381 |
| Dexamethasone Sodium Phosphate | 13 | $735 |
| Cefdinir | 37 | $649 |
| Ofloxacin | 20 | $634 |
| Mupirocin | 86 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $489 | $6,59111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Plantation
- Juan Armando Chiossone KerdelPlantation$27K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
- David BrodnerBoynton Beach$209K
- Maria SuurnaMiami$189K
- Jane DillonOrmond Beach$180K
- Jeb JusticeGainesville$142K
- Indranil DebnathWinter Park$109K
- Agustin ArrietaMiami$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.